Survey of public information about ongoing clinical trials funded by industry: evaluation of completeness and accessibility
BMJ 2002; 325 doi: https://doi.org/10.1136/bmj.325.7363.528 (Published 07 September 2002) Cite this as: BMJ 2002;325:528
Data supplement
Table A Prostate cancer and colon cancer drugs, and their alternate names, included in phase III trials listed in three drug industry "pipeline" sources NDA Pipeline, PhRMA 1999 Survey, and What’s in the Pipeline June 1999 and June 2000
Name (developer(s))
Alternative names
Prostate cancer drugs
AG3340 (Agouron)
AG3340 MMPI, AG3340 MMP
ALRT-1057 (Ligand)
9-CIS retinoic acid, Panretin, Alitretinoin, LGD1057
Aredia (Novartis)
Pamidronate Sodium
Bicalutimide (AstraZeneca)
Casodex
BMS-217380 (Bristol-Myers Squibb)
Tesmilifene hydrochloride
Duros leuprolide (Alza)
Exisuland (Cell Pathways)
Exisulind, FGN-1, Aptosyn, Prevatac
Goserelin acetate (AstraZeneca)
Zoladex
Leuprolide acetate (Atrix)
ATRIGEL
PPI-149 (Praecis)
Abarelix, Abarelix-Depot, LHRH
RL-0903 (Roberts)
LHRH-hydrogel, GHR factor agonist
SU101 (Sugen)
Leflunomide, PDGF TK Inhibitor
Colon cancer drugs
Anti-Gastrin (Aventis)
Avicine (AVI BioPharma)
capecitabine (Hoffman- La Roche)
Xeloda
CeaVac (Titan Pharmaceuticals)
anti-idiotype antibody
irinotecan, Campto Camptosar NSLC, Camptosar, Camptosar NSLC
edrecolomab (GlaxoSmithKline)
edrecolomab monoclonal antibody, Panorex
eflornithine (ILEX Oncology)
Eloxatin (Sanofi Pharmaceuticals)
oxaliplatin
eniluracil (GlaxoSmithKline)
776C85
Exisuland (Cell Pathways)
Aptos, exisulind, Aptosyn
Mab 17-1A (GlaxoSmithKline/NCI)
MOAB 17-1A/GM-CSF, monoclonal antibody 17-1A
multitargeted antifolate (Eli Lilly)
antifolate breast and colon cancer, Alimta
neutralize hormone G17 (Aphton)
Gastrimmune
Octreotide acetate (Novartis)
octreotide, Sandostatin LAR, Sandostatin LAR Depot
OncoVAXcl (Intracel)
autologous vaccine, OncoVAX
Raltitrexed (AstraZeneca)
Tomudex
recombinant interferon-beta-1a (Serono)
SU-5416 (Sugen)
fetal liver kinase-1 inhibitor
trimetrexate glucuronate (US Bioscience)
NeuTrexin, trimetrexate glucuronate
VEGF (Genentech)
Anti-VEGF, Anti-VEGF humanized monoclonal antibody
Related articles
- This Week In The BMJ Published: 07 September 2002; BMJ 325 doi:10.1136/bmj.325.7363.0/f
Cited by...
- Systematic review protocol assessing the processes for linking clinical trial registries and their published results
- Including Persons With HIV Infection in Cancer Clinical Trials
- Trends in Clinical Trials Reports in Common Cancers Between 1989 and 2000
- A clinical trials register for Europe